Literature DB >> 3608532

High-dose naloxone: pharmacokinetics in patients in septic shock.

J S Groeger, C E Inturrisi.   

Abstract

Naloxone, a commonly used narcotic antagonist, may be beneficial in reversing the hemodynamic alterations seen in septic shock. In normal subjects, naloxone pharmacokinetics are characterized by rapid distribution and elimination. We investigated the pharmacokinetics of high-dose naloxone in four patients with septic shock and multiorgan failure. The pharmacokinetics of naloxone in these patients can be described by a two-compartment model with a rapid alpha distribution similar to that observed in normal humans. However, in these critically ill patients there was virtually no drug elimination as levels were followed for 5 h post-termination of a 6-h infusion of 2.4 mg/kg X h. This dramatic accumulation of naloxone may explain why responses have been reported by others to small doses of naloxone in septic shock patients. No significant side-effects were seen in our patients with plasma naloxone levels as high as 3.78 micrograms/ml. Caution is warranted when one administers naloxone to patients whose ability to eliminate this drug is minimal.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608532

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

Review 1.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

Review 2.  Naloxone in opioid poisoning: walking the tightrope.

Authors:  S F J Clarke; P I Dargan; A L Jones
Journal:  Emerg Med J       Date:  2005-09       Impact factor: 2.740

Review 3.  Naloxone dosage for opioid reversal: current evidence and clinical implications.

Authors:  Rachael Rzasa Lynn; J L Galinkin
Journal:  Ther Adv Drug Saf       Date:  2017-12-13

Review 4.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 6.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.